Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026GlobeNewsWire · 1 day ago
Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 2.7% – Time to Sell?Defense World · Oct 4, 2026
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis ConferenceGlobeNewsWire · Sep 14, 2026
Pasithea Therapeutics Announces Participation in Two September 2026 Investor ConferencesGlobeNewsWire · Sep 3, 2026
Reviewing Oncobiologics (NASDAQ:OTLK) and Pasithea Therapeutics (NASDAQ:KTTA)Defense World · Aug 12, 2026Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.16 | -$0.16 | Beat |
| May 15, 2026 | -$0.45 | -$0.12 | Beat |
| Mar 30, 2026 | -$0.18 | -$0.89 | Miss |
| Nov 13, 2025 | -$0.18 | -$0.41 | Miss |
| Aug 14, 2025 | – | -$0.66 | |
| May 15, 2025 | – | -$1.61 |